Neurocrine Biosciences, Inc. has received $-0.54 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 9 Financial Advisor in the Stock Trading Firms. Among 9 Analysts, Bottom line EPS Estimate for the current quarter is $-0.6 while the top line estimate is $-0.49 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -60.13%.
Neurocrine Biosciences, Inc. reported better than expected with a surprise EPS of 24.56% or $0.14 during its most recent quarterly earnings. The Actual EPS was $-0.43 compared to the Estimated EPS of $-0.57.
In the last quarter, Neurocrine Biosciences, Inc. reported Annual Earnings of $-0.43. Based on the filings, last years Annual Earnings was, $-1.05. In the last Quarter, NBIX reported a surprise Earnings per Share of 24.56% . The consensus estimate for current quarter is $-0.54 and for the current fiscal year, the estimate is $-1.66. For the Next fiscal year, the estimate is $-1.82 based on the consensus.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) : On Tuesday heightened volatility was witnessed in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) which led to swings in the share price. The stock opened for trading at $39.63 and hit $43 on the upside , eventually ending the session at $42.91, with a gain of 6.93% or 2.78 points. The heightened volatility saw the trading volume jump to 1,399,566 shares. The 52-week high of the share price is $55.15 and the company has a market cap of $3,728 million. The 52-week low of the share price is at $31.25 .
Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The companys neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.